Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | BRD2 | P25440 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL635055 | 0.78 | MAPT (0.39) | MAPTL3MBTL1POLBMAPK1GABRA1 | |
| SCHEMBL5431677 | 0.71 | PTGS1 (0.53) | MAPTBRD4BRD2 | |
| SCHEMBL15920150 | 0.70 | — | — | |
| SCHEMBL1904432 | 0.65 | BRD4 (0.38) | MAPTL3MBTL1POLBMAPK1BRD4 | |
| SCHEMBL27500197 | 0.65 | MAPT (0.37) | MAPTL3MBTL1POLBMAPK1BRD4 | |
| SCHEMBL16707454 | 0.65 | GABRA1 (0.41) | GABRA1GABRB2 | |
| SCHEMBL21406545 | 0.64 | GAA (0.40) | — | |
| SCHEMBL21406544 | 0.64 | GAA (0.40) | — | |
| SCHEMBL21406550 | 0.64 | GAA (0.40) | — | |
| SCHEMBL18247010 | 0.63 | GPR6 (0.41) | MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| EP-1844044-B1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-07-21 | — | — | EP | disclosed |
| EP-2205561-A2 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | Novartis Ag (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-7678815-B2 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| WO-2009050197-A2 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
| US-20090099199-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-04-16 | — | — | US | disclosed |
| EP-1844044-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | HOFFMANN-LA ROCHE INC. | 2006-07-20 | — | — | US | disclosed |
| WO-2006074884-A1 | THIAZOLE-4-CARBOXAMIDE DERIVATIVES AS MGLUR5 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-07-20 | — | — | WO | disclosed |
| CN-1780822-A | Use of derivatives of 2, 4-dihydro- 1,2,4 triazole-3-thione as inhibitors of the enzyme myeloperoxidase (MPO) | ASTRAZENECA AB (SE) | 2006-05-31 | — | — | CN | disclosed |
| EP-1620410-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO- 1,2,4 TRIAZOLE-3-THIONE AS INHIBITORS OF THE ENZYME MYELOPEROXIDASE (MPO) | AstraZeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2004096781-A1 | USE OF DERIVATIVES OF 2, 4-DIHYDRO-[1,2,4]TRIAZOLE-3-THIONE AS INHIBITORS O FTEH ENZYME MYELOPEROXIDASE (MPO) | ASTRAZENECA AB (SE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160857-A1 | Thiazole-4-carboxyamide derivatives | GRM1, GRM2, GRIA4 | MAPT 3444/4885L3MBTL1 2724/4885POLB 4841/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MAPT 2356/4885L3MBTL1 4142/4885POLB 3826/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | MAPT 2776/4885L3MBTL1 2508/4885POLB 137/4885 |
| US-20090099199-A1 | ORGANIC COMPOUNDS | SLCO4C1, SLC10A6, SLCO1B1 | MAPT 1192/4885L3MBTL1 4651/4885POLB 1233/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | MAPT 2356/4885L3MBTL1 4142/4885POLB 3826/4885 |
| US-20070093483-A1 | Use of derivatives of 2, 4-dihydro-[1,2,4] triazole-3-thione as inhibitors of the enzyme myeloperoxidase (mpo) | MPO, XDH, EPX | MAPT 2326/4885L3MBTL1 3772/4885POLB 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.